(I Can’t Get No) Satisfaction: OPDP Untitled Letter Challenges Implied Superiority Claims in HCP Newsletter

Key Takeaways

• The Food and Drug Administration issued an Untitled Letter finding that a healthcare provider (“HCP”)-directed newsletter promoting an FDA-approved botulinum toxin product was false or misleading under the Federal Food, Drug, and Cosmetic Act (“FD&C Act”).
• The newsletter implied that the product’s manufacturing process and formulation offered clinical advantages over competing products without adequate evidence to support those claims.
• FDA also challenged claims suggesting reduced diffusion and antibody formation, finding that the cited evidence did not substantiate those implications and that certain statements minimized a serious safety risk.
• The letter highlights the importance of substantiating implied comparative claims and ensuring that branded scientific materials accurately reflect the evidence and approved labeling.

FDA OPDP Identifies Unsupported Superiority and Safety Claims

The latest Untitled Letter from FDA’s Office of Prescription Drug Promotion (“OPDP”) illustrates the risks associated with promotional claims that imply clinical advantages based on a product’s manufacturing process or formulation. FDA reviewed a professional newsletter promoting an FDA-approved botulinum toxin type A product.

FDA concluded that the newsletter was false or misleading, misbranded the product, and caused its distribution to violate the FD&C Act.¹ Perhaps while singing the Rolling Stones’ “(I Can’t Get No) Satisfaction,” the agency identified several concerns.

Manufacturing and Formulation Claims Implied Unsupported Clinical Superiority

The newsletter stated “Manufacturing matters — not all toxins are created equal,” and urged hcps to “ensure patients get the full benefits of treatment.”

It also linked the product’s vacuum-drying process and formulation to “full efficacy.” FDA interpreted these statements as implying unique or additional clinical benefits over other FDA-approved botulinum toxin products. The agency stated that it was unaware of head-to-head studies supporting those advantages and invited the company to submit supporting information or data.

FDA Rejects Scientific Support for Comparative Efficacy and Diffusion Claims

The newsletter asserted that nontoxin accessory proteins (“NAPs”) contributed to botulinum neurotoxin type A activity and suggested that formulations containing NAPs could reduce glabellar strain more effectively than non-complexed formulations.

The materials also suggested that a larger molecular structure “may diffuse less.” FDA found that the cited review article discussed potential effects of manufacturing and formulation characteristics but did not establish the claimed comparative clinical benefits. FDA also concluded that the diffusion statement minimized the serious risk of distant spread of toxin effects described in the product’s Boxed Warning.

Clinical Data Failed to Substantiate Reduced Immunogenicity Claims

The newsletter linked the manufacturing process to a lower risk of antibody formation and suggested that vacuum-dried formulations produced no antibodies following clinical exposure. FDA concluded that these statements implied that the process reduced or eliminated antibody formation without adequate support.

Although a phase II study reported treatment-emergent antibodies in two subjects receiving a freeze-dried formulation, the study only theorized about a possible association with manufacturing differences. Phase III trials using the final commercial formulation reported no subsequent positive antibody tests among subjects who were negative at baseline, but FDA found that these results did not establish reduced immunogenicity risk. FDA also cited the Prescribing Information’s cautions that antibody detection depends on assay sensitivity and specificity, and that comparisons across studies or products may be misleading.

What FDA’s Untitled Letter Means for Pharmaceutical Companies

• Comparative claims should be supported by evidence that substantiates the benefit implied. Statements about formulation, manufacturing, or molecular characteristics may imply clinical superiority even without an express comparison of clinical outcomes.
  • Where a communication implies a clinical advantage over competing products, mechanistic explanations or indirect evidence may be misleading. Companies should aim to only make direct comparative claims if they have head-to-head clinical evidence.
• Scientific citations must support the specific promotional message. Citing a review article or clinical study does not, by itself, substantiate a promotional claim.
  • Reviewers should determine whether the source supports the particular benefit or comparison conveyed, considering study design, endpoints, limitations, and conclusions.
  • Here, FDA found that the cited literature did not establish the claimed comparative benefits or support the manufacturing process claims.
• Mechanism-of-action claims can imply unsupported superiority. Descriptions of molecular structure, accessory proteins, and manufacturing processes may appear scientifically neutral but can imply clinical advantages in a promotional context.
  • FDA’s analysis underscores the importance of evaluating a communication’s overall impression, including its headlines, scientific explanations, and efficacy statements.
• Claims must not minimize material safety risks. FDA objected to the suggestion that a larger molecular structure “may diffuse less,” finding that it minimized the serious risk of distant spread of toxin effects described in the product’s Boxed Warning.
  • Promotional claims should not imply a degree of safety or predictability that the evidence does not establish or diminish material risks identified in approved labeling.
• HCP-directed materials remain subject to promotional requirements. The newsletter’s scientific tone and professional audience did not insulate it from scrutiny.
  • Companies should evaluate branded newsletters and educational materials for substantiation, balance, and overall impression, just as they would other promotional communications.
• Similar claims may warrant review across promotional channels. FDA’s request to identify other communications containing similar representations highlights the value of reviewing related materials, including sales aids, congress materials, digital communications, and other branded resources, when a claim is challenged.

FDA’s Untitled Letter is a reminder that claims can be both factual accurate and misleading in context.  Companies should assess whether their scientific explanations and supporting citations substantiate the clinical message conveyed to HCPs. Much like the Rolling Stones, OPDP remains unsatisfied when promotional claims promise more than the data can deliver.

For guidance on these issues, please contact a member of AGG’s Food & Drug team.

[1] FDA publishes Untitled Letters here.